Latest news with #pharmacology
RNZ News
21-05-2025
- Health
- RNZ News
Feature interview: Rethinking medications
health author interview 41 minutes ago Breakthrough drugs are changing medicine, offering new hope in pill form. But the system meant to protect patients is under strain. The U.S. develops over 40% of new medications, and the FDA plays a central role in ensuring their safety. Harvard pharmacology professor Dr. Jerry Avorn says industry pressure has quietly weakened FDA standards, allowing risky or barely effective drugs to slip through. In his new book he reveals how this happened and shares practical advice for patients trying to make decisions about what we are willing to swallow. The book is called Rethinking Medications: Truth, Power, and the Drugs You Take.
Business Wire
14-05-2025
- Business
- Business Wire
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter ended March 31, 2025. 'The first quarter of 2025 was highlighted by continued progress in the development of EB-003, our neuroplastogenic molecule that is designed to address difficult-to-treat mental health disorders,' said Joseph Tucker, Ph.D., CEO and Director of Enveric. 'We continue to focus our development efforts on the completion of the data package to support filing an Investigational New Drug (IND) application for EB-003, which we aim to submit to the FDA by the end of the first quarter of 2026.' Dr. Tucker said: 'Ongoing development of EB-003 is supported by the data accumulated to date, which have demonstrated oral bioavailability and brain exposure in preclinical studies. Preclinical work has also shown encouraging pharmacology and safety results from in vitro pharmacology studies.' Dr. Tucker added: 'Enveric continues to expand the portfolio of intellectual property covering our proprietary technologies, including the recent receipt of a Notice of Allowance from the USPTO for claims covering EB-003 composition of matter. We also announced the issuance of a U.S. patent for our EVM401 Series, a collection of mescaline derivative compounds that broadens Enveric's potential to develop additional neuroplastogenic therapeutics for addiction and neuropsychiatric disorders. Preliminary testing of our EVM401 series and their metabolites has demonstrated differentiated and encouraging patterns of brain receptor binding and/or activation.' Dr. Tucker concluded: 'As we look ahead to the remainder of 2025 and beyond, we are confident that Enveric is at the leading edge of a paradigm shift in the treatment of severe mental health conditions, an area that has seen minimal innovation for decades. We look forward to bringing our novel technologies to patients in need, while generating value for our shareholders as we capitalize on the substantial potential of the emerging field of neuroplastogenic therapeutics.' FIRST QUARTER AND RECENT UPDATES Corporate, Product and Business Development Highlights: Unveiled EVM401 Series with new U.S. Patent for mescaline derivative compounds, broadening Enveric's pipeline of neuroplastogen candidates for addiction and neuropsychiatric disorders Added to suite of intellectual property for EB-003, a neuroplastogen targeting undertreated mental health indications Signed two licensing agreements with Restoration Biologics LLC, for cannabinoid-COX-2 conjugate compounds, with plans to investigate potential to treat joint pathologies, such as osteoarthritis and rheumatoid arthritis, creating the potential for diversified future revenue streams Announced closing of $5 million public offering FIRST QUARTER FINANCIAL RESULTS Net loss attributable to stockholders was $2.2 million for the first quarter ended March 31, 2025, including $0.3 million in net non-cash expense, with a basic and diluted loss per share of $1.22, as compared to a net loss of $2.5 million, including $0.4 million in net non-cash income, with a basic and diluted loss per share of $9.21 for the quarter ended March 31, 2024. The Company had cash-on-hand of $4.3 million for the quarter ended March 31, 2025. About Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Medscape
09-05-2025
- Health
- Medscape
Fast Five Quiz: Management of Achondroplasia
Achondroplasia is the most common form of skeletal dysplasia and is associated with numerous complications that require careful monitoring and management. This form is typically diagnosed at birth or during infancy; treatment can begin around this point to mitigate future complications, though achondroplasia usually requires lifelong management. Surgical interventions are often necessary to address specific complications, and recent advances in pharmacologic treatment have also been added to the management of this condition. Regardless, achondroplasia still impacts quality of life. Do you know how to effectively manage achondroplasia? Check your knowledge with this quick quiz.
Associated Press
30-01-2025
- Health
- Associated Press
Medical Experts to Examine Kratom CME Symposium This Friday
Hosted by the Tulane University Center for Continuing Education, seminar brings together leading researchers and clinicians to explore the reality of kratom use in the U.S. NEW ORLEANS, LA, January 30, 2025 (EZ Newswire) -- A distinguished panel of researchers and clinicians will gather for a Continuing Medical Education (CME) symposium on Friday, January 31, 2025, to explore one of the most talked-about and often misunderstood topics in healthcare today—kratom. The symposium, hosted by the Tulane University Center for Continuing Education, will take place in New Orleans and will also be available virtually. It will feature leading experts in pharmacology, toxicology, addiction medicine, and psychiatry, examining the latest scientific research and clinical experiences surrounding kratom use. Event Details Date: Friday, January 31, 2025 Time: 12:00 PM – 4:00 PM CST In-person location: Tulane Tidewater Building, 1440 Canal St, New Orleans, LA 70112 ME credit: Up to 3.5 AMA PRA Category 1 Credits™ Complimentary registration: Click here to register. Expert-Led Discussions on Kratom's Impact With kratom use becoming more widespread in the U.S., healthcare professionals face increasing questions about its safety, potential benefits, and risks. This symposium provides a rare opportunity for clinicians and researchers to hear directly from nationally recognized experts studying kratom's pharmacology, clinical implications, and potential benefits and risks. Featured Speakers Dr. Christopher McCurdy, Associate Dean for Faculty Development, Frank A. Duckworth Eminent Scholar Chair, Professor of Medicinal Chemistry, and Director of the UF CTSI Translational Drug Development Core at the University of Florida. Dr. McCurdy's pioneering research explores kratom's pharmacology, its potential therapeutic uses, and the critical role of dosing in research and policy. Dr. Oliver Grundmann, Assistant Dean and Clinical Professor at the University of Florida. Dr. Grundmann is a leading expert on kratom consumer trends, providing insight into who is using kratom, why, and the clinical implications of these patterns. Dr. John Thompson, Chairman and Professor of the Department of Psychiatry and Behavioral Sciences at Tulane University School of Medicine. Dr. Thompson and faculty members from Tulane's psychiatry department will present real-world case studies from their work in emergency medicine, addiction treatment, pain management, and psychiatric care. Learner Objectives After participating in this symposium, attendees should be better able to: Identify historical and indigenous uses of kratom for pain, sleep, and opioid replacement disorders. Describe current kratom usage trends in the U.S., including administration routes, servings, and consumer access. Discuss problematic kratom use, including common emergency room, addiction clinic, and pain practice presentations. Suggest legislative solutions to enhance safety. Accreditation and CME Details Tulane University Health Sciences Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Tulane University Health Sciences Center designates this live educational activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity is presented for educational purposes only and does not endorse any product, content, or exhibit. Participants are expected to apply their own expertise and clinical judgment while engaging in medical practice. Who Should Attend? Designed for physicians, psychiatrists, healthcare professionals, addiction specialists, toxicologists, pain management specialists, pharmacists, researchers, and policymakers, this symposium will provide evidence-based discussions on kratom's risks, potential benefits, and risks. The Global Kratom Coalition is an alliance of kratom consumers, experts, and industry leaders dedicated to protecting access to kratom while advancing scientific research, driving consumer education, and developing robust regulations to protect consumers. Media Contact
